Trial Profile

A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating Neoadjuvant Therapy Targeting the Adenosine Immunosuppressive Pathway in Combination With Immune Checkpoint Blockade and Radiation Therapy in Patients With Advanced PANCreatic Ductal Adenocarcinoma Who Are Candidates for Surgical Resection

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etrumadenant (Primary) ; Quemliclustat (Primary) ; Zimberelimab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin; Pegfilgrastim
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Therapeutic Use
Acronyms AIRPanc

27 Feb 2024 Planned initiation date (estimated date of first participant enrollment) changed from 1 Oct 2023 to 1 Jun 2024.
20 Jan 2024 Trial design, presented at the 2024 Gastrointestinal Cancers Symposium
26 Sep 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com